<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1911246279
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Enrylaze
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RECOMBINANT CRISANTASPASE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11250.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Manufacturing Services LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Manufacturing Services LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazz Pharmaceutical Ireland Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Enrylaze&reg; contains the active substance recombinant crisantaspase. It is a medicine used alongside other medicines to treat acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). Enrylaze&reg; can be given to patients aged 1 month of age or older.</p><p>Enrylaze&reg; contains a protein made in the laboratory by recombinant DNA technology. This protein works by decreasing the amount of a protein called asparagine. This protein is needed by the ALL and LBL cancer cells to survive.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not receive Enrylaze&reg; </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe allergic reaction to Enrylaze&reg;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an allergic reaction to any of the other ingredients of this medicine (listed in<br />section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are currently experiencing severe pancreatitis (inflammation of the pancreas).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have experienced severe pancreatitis after being treated with asparaginase therapies.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have experienced serious blood clots after being treated with asparaginase therapies.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have experienced serious bleeding events after being treated with asparaginase therapies.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before you receive Enrylaze&reg;.</p><p>&nbsp;</p><p>The following problems may occur during treatment with Enrylaze&reg;:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reactions that may be life threatening. The hospital will ensure they are prepared to address any allergic reactions that may occur during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your pancreas. Discomfort or pain in your stomach or back area may be a sign of pancreatitis and should be reported to your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in your body&rsquo;s ability to manage blood sugar levels. Your doctor should monitor your glucose levels whilst on treatment and provide insulin if necessary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual bleeding events or blood clots. If either of these events occur treatment will be paused by your doctor until they are resolved.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issues with your liver. Your doctor will monitor you to identify if you are experiencing any issues with your liver and treat you as necessary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; central nervous system toxicity, such as seizures and impaired neurological function. Also, instances of posterior reversible encephalopathy syndrome (characterised by headache, confusion, seizures and loss of vision) may require blood-pressure lowering medicines and in case of seizure, treatment with anti-epileptic medicines.</p><p>&nbsp;</p><p><strong>Monitoring during treatment with Enrylaze&reg;</strong></p><p>You will be monitored during and after treatment with Enrylaze&reg; for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; functioning of your pancreas and liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood sugar levels</p><p>&nbsp;</p><p><strong>Other medicines and Enrylaze&reg;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular inform your doctor or pharmacist if you have or are receiving:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate or cytarabine, used in cancer treatment. Use of these medicines immediately before Enrylaze&reg; may increase their effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vincristine, used in cancer treatment. Use of vincristine with Enrylaze&reg; may increase the toxicity of vincristine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glucocorticoids, used as anti-inflammation medicines. Use of these medicines immediately before Enrylaze&reg; may increase the formation of blood clots.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>Enrylaze&reg; should not be used during pregnancy, and women should check they are not pregnant prior to starting therapy. If you are pregnant or think you may be pregnant, ask your doctor or pharmacist for advice before receiving this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>You should not breast-feed during treatment and for two weeks following treatment with Enrylaze&reg;, as there may be a risk to the breast-feeding child.</p><p>&nbsp;</p><p><strong>Family planning</strong></p><p>Both men and women should use a form of contraception and avoid conceiving a child during treatment with Enrylaze&reg; and for 3 months after you last receive Enrylaze&reg;. Hormonal contraceptives are not recommended for use in women when being treated with Enrylaze&reg;.</p><p>&nbsp;</p><p>Women should undergo pregnancy testing before starting treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Enrylaze&reg; can cause you to feel sick and have a headache. This may impact your ability to drive and operate machines.</p><p>&nbsp;</p><p><strong>Enrylaze&reg; contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23&nbsp;mg) per dose unit, that is to say essentially &lsquo;sodium free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Your doctor will determine what dose you are given and whether it will be given to you by an infusion into your veins or an injection into your muscle. You may also be given some other medicines before you start receiving Enrylaze&reg;, such as paracetamol H1 and H2 blocker.</p><p>&nbsp;</p><p>The dose and how it is given may vary depending on your specific condition, body surface area and response to therapy.</p><p>&nbsp;</p><p>If you are given Enrylaze&reg; into your veins, this will be given over a 2‑hour period. If you are given Enrylaze&reg; into a muscle, several injection sites may be used.</p><p>&nbsp;</p><p><strong>If you think you have been given more Enrylaze&reg; than you should</strong></p><p>If you have any concerns, contact your doctor or any healthcare professional immediately.</p><p>&nbsp;</p><p><strong>If you think you have missed a dose of Enrylaze&reg;</strong></p><p>If you have any concerns, contact your doctor or any healthcare professional immediately.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. For patients treated with Enrylaze&reg; the following side effects were reported.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Tell your doctor immediately if you experience:</strong></p><p>Symptoms of a serious allergic reaction, including swelling of the face, shortness of breath, hay fever like symptoms, rash, chills, wheezing, flushing, vomiting, high or low blood pressure. In severe cases anaphylaxis (a sudden, severe allergic reaction with breathing difficulty, swelling,</p><p>light-headedness, fast heartbeat, sweating and loss of consciousness) can also occur.</p><p>&nbsp;</p><p>Symptoms of blood clots, including in the blood vessels of the lung which could present as sudden shortness of breath, chest pain, or coughing up blood and the blood vessels of the brain which could present with symptoms such as weakness/numbness, seizure, trouble speaking, or severe headache.</p><p>&nbsp;</p><p>Symptoms of pancreatitis, including abdominal pain, nausea, vomiting, back pain, or loss of appetite.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Talk to your doctor if you get any of the following:</p><p>&nbsp;</p><p><strong>Very common </strong>side effects (may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction, including rash, itching, and hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of blood platelets (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of white blood cells (white blood cell count decreased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of neutrophils, a type of white blood cell that fights off infection (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of white blood cells (neutrophils) with fever due to infection (febrile neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of lymphocytes, a type of white blood cell that fights off infection (lymphocyte count decreased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your stomach (abdominal pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar levels (hyperglycaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in limbs (pain in extremity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss (weight decreased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function test (transaminases increased, blood bilirubin increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased albumin (a blood protein) level (hypoalbuminaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising (contusion)</p><p>&nbsp;</p><p><strong>Common</strong> side effects (may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood poisoning (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden, severe allergic reaction with breathing difficulty, swelling, lightheadedness, fast heartbeat, sweating and loss of consciousness (anaphylactic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash characterized with flat, discolored patches (macules) and raised, reddened bumps (papules) (rash maculo-papular)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash with redness and inflamation (rash erythematous)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy skin (pruritus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (pancreatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion related reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal blood clotting factor levels (prolonged activated partial thromboplastin time, decreased antithrombin III, decreased blood fibrinogen)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal kidney function (increased blood creatinine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar levels (hypoglycaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots, including in the blood vessels of the lung and brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&nbsp;</p><p><strong>Uncommon</strong> side effects (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in a major brain vein (superior sagittal sinus thrombosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in the neck vein (jugular vein thrombosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in extremity veins (deep vein thrombosis)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via</p><p>&nbsp;</p><p>&bull; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull; <strong>Kuwait:</strong></p><p>Drug &amp; Food Control, Ministry of Health, Kuwait</p><p>&bull; Tel. No.: +965-24811532</p><p>&bull; Fax No.: +965-24811507</p><p>&bull; E-mail: Adr_reporting@moh.gov.kw</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store the unopened vials in a refrigerator (2&nbsp;&deg;C&ndash;8&nbsp;&deg;C) in an upright position. Do not freeze. Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>After preparing a dose in a syringe, Enrylaze&reg; can be stored for up to 8 hours at room temperature (15&deg;C&ndash;25&nbsp;&deg;C) or 24 hours when refrigerated (2&nbsp;&deg;C&ndash;8&nbsp;&deg;C).</p><p>&nbsp;</p><p>After dilution in an intravenous bag, Enrylaze&reg; can be stored for up to 12&nbsp;hours at room temperature (15&nbsp;&deg;C&ndash;25&nbsp;&deg;C) or 24 hours when refrigerated (2&nbsp;&deg;C&ndash;8&nbsp;&deg;C). Storage time starts once the solution has been withdrawn from the unopened vials.</p><p>&nbsp;</p><p>Do not use this medicine if you notice any particles in the solution.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is recombinant crisantaspase. Each vial contains 10&nbsp;mg of recombinant crisantaspase in 0.5 mL solution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are trehalose dihydrate, sodium chloride (see section&nbsp;2 &ldquo;Enrylaze&reg; contains sodium&rdquo;), sodium hydroxide (for pH adjustment), disodium phosphate, sodium dihydrogen phosphate monohydrate, polysorbate&nbsp;80 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Enrylaze® is a clear to slightly yellow solution for infusion or injectionn, free from particulate matter.

One carton contains 3 glass vials, each with 0.5 mL of solution for infusion or injection.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Batch release site:</strong></p><p>Jazz Pharmaceuticals Ireland Ltd</p><p>5th Floor</p><p>Waterloo Exchange</p><p>Waterloo Road</p><p>Dublin 4</p><p>D04 E5W7</p><p>Ireland</p><p>Tel: +353 1 968 1631</p><p>Email: medinfo-int@jazzpharma.com</p><p>&nbsp;</p><p><strong>Bulk Manufacturer:</strong></p><p>Patheon Manufacturing Services,</p><p>LLC 5900 Martin Luther King Jr. Highway,</p><p>Greenville,</p><p>NC 27834-8628</p><p>United States</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder in KSA and Kuwait:</p><p>&nbsp;</p><p><u>KSA</u></p><p>Biologix, FZ Co, Hibatullah Al Ghaffari Street-Suliemaniah Kingdom of</p><p>Saudi Arabia P.O.Box 991, Riyadh 11421.</p><p>Tel: +966 11 464 6955</p><p>Fax: +966 11 463 4362</p><p><strong>&nbsp;</strong></p><p><u>Kuwait</u></p><p>Medinfo@biologixpharma.com</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي إنريلاز على المادة الفعالة كريسانتاسباس المؤتلف، وهو دواء يستخدم إلى جانب أدوية أخرى لعلاج سرطان الدم الليمفاوي الحاد وسرطان الخلايا الليمفاوية.</p><p dir="RTL">يمكن إعطاء إنريلاز للمرضى الذين تبلغ أعمارهم شهرًا واحدًا و ما فوق.</p><p dir="RTL">يحتوي إنريلاز على بروتين تم تصنيعه في المختبر بواسطة تقنية الحمض النووي المؤتلف، حيث يعمل هذا البروتين عن طريق تقليل كمية البروتين المسمى الأسباراجين. تحتاج الخلايا السرطانية في سرطان الدم الليمفاوي الحاد وسرطان الخلايا الليمفاوية إلى هذا البروتين من أجل البقاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب عليك أن تأخذ إنريلاز: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك رد فعل تحسسي شديد تجاه إنريلاز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك رد فعل تحسسي تجاه أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حالياً من التهاب حاد في البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب حاد في البنكرياس بعد علاجك باستخدام أنزيم الأسباراجيناز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت لجلطات دموية خطيرة بعد العلاج باستخدام أنزيم الأسباراجيناز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت لحالات نزيف خطيرة بعد العلاج باستخدام أنزيم الأسباراجيناز</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والمحاذير</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلاني قبل أن يتم إعطاؤك إنريلاز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث المشكلات التالية أثناء العلاج بإنريلاز:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة قد تكون مهددة للحياة. سيتأكد المستشفى من استعدادهم لمعالجة أية تفاعلات حساسية قد تحدث أثناء العلاج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس. قد يكون الشعور بالانزعاج أو الألم في منطقة المعدة أو الظهر علامة على التهاب البنكرياس ويجب إبلاغ طبيبك على الفور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في قدرة الجسم على إدارة مستويات السكر في الدم. يجب على طبيبك مراقبة مستويات الجلوكوز أثناء العلاج وتوفير الأنسولين إذا لزم الأمر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث نزيف غير اعتيادي أو جلطات دموية. في حالة حصول أي من هذه الأحداث، فسيتم إيقاف العلاج مؤقتًا من قبل طبيبك حتى يتم حلها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد. سيقوم طبيبك بمراقبتك لتحديد ما إذا كنت تعاني من أية مشاكل في الكبد وعلاجك عند الضرورة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سمّيّة الجهاز العصبي المركزي مثل النوبات وضعف الوظيفة العصبية. كما أن حالات متلازمة اعتلال الدماغ العكسي الخلفي (التي توصف بحدوث بالصداع والتشوش والتشنجات وفقدان الرؤية) قد تتطلب أدوية لخفض ضغط الدم، وفي حالة التشنجات، سيتم العلاج بالأدوية المضادة للصرع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراقبة أثناء العلاج بإنريلاز</strong></p><p dir="RTL">ستتم مراقبتك أثناء وبعد العلاج باستخدام إنريلاز من أجل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أداء وظائف البنكرياس والكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات السكر في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع إنريلاز</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلاني إذا كنت تتناول، أو تناولت مؤخرًا، أو من الممكن أن تتناول أية أدوية أخرى. أخبر طبيبك أو الصيدلاني على وجه الخصوص إذا كنت تتلقى أو قد تلقيت:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات أو سيتارابين المستخدمان في علاج السرطان. إن استخدام هذه الأدوية مباشرة قبل إنريلاز قد يزيد من تأثيرها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينكريستين المستخدم في علاج السرطان، حيث أن استخدام فينكريستين مع إنريلاز قد يزيد من سمّيّة فينكريستين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلوكورتيكويدات المستخدمة كأدوية مضادة للالتهاب. إن استخدام هذه الأدوية مباشرةً قبل إعطاء إنريلاز قد يزيد من تكوين جلطات الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">لا ينبغي استخدام إنريلاز أثناء الحمل، ويجب على النساء التحقق من عدم وجود حمل قبل بدء العلاج. إذا كنتِ حاملاً أو تعتقدين أنك حامل، فاطلبي المشورة من طبيبك أو الصيدلاني قبل تلقي هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">يجب عليكِ عدم الإرضاع رضاعة طبيعية أثناء العلاج ولمدة أسبوعين بعد العلاج بإنريلاز؛ حيث قد يكون هناك خطر على الطفل الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تنظيم الأسرة</strong></p><p dir="RTL">يجب على كل من الرجال والنساء استخدام أحد أشكال وسائل منع الحمل وتجنب الحمل أثناء العلاج بإنريلاز ولمدة 3 أشهر بعد آخر تلقي لإنريلاز. لا يُنصح باستخدام وسائل منع الحمل الهرمونية من قبل النساء أثناء العلاج بإنريلاز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على النساء إجراء فحص حمل قبل بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب لك إنريلاز الشعور بالغثيان والصداع، وقد يؤثر ذلك على قدرتك على القيادة وتشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي إنريلاز على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل وحدة جرعة، وهذا يعني أنه خالٍ من الصوديوم بشكل أساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />&nbsp;</p><p dir="RTL">سيحدد طبيبك الجرعة التي تعطى لك وما إذا كان سيتم إعطاؤها لك عن طريق التسريب في الوريد أو الحقن في العضل. قد يتم إعطاؤك أيضًا بعض الأدوية الأخرى قبل البدء في تلقي إنريلاز مثل حاصرات H1 &nbsp;وH2 الباراسيتامول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تختلف الجرعة وكيفية إعطائها اعتمادًا على حالتك المحددة ومساحة سطح الجسم والاستجابة للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم إعطاؤك إنريلاز في الوريد، فسيتم إعطاؤه على مدار ساعتين، أما إذا تم إعطاؤك إنريلاز في العضل، فقد يتم استخدام عدة مواضع للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعتقد أنك تلقيت كمية إنريلاز أكثر مما ينبغي</strong></p><p dir="RTL">إذا كانت لديك أية مخاوف، اتصل بطبيبك أو أي أخصائي رعاية صحية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعتقد أنه قد تم تفويت جرعة من إنريلاز</strong></p><p dir="RTL">إذا كانت لديك أية مخاوف، اتصل بطبيبك أو أي أخصائي رعاية صحية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها قد لا تصيب الجميع. بالنسبة للمرضى الذين عولجوا بإنريلاز فقد تم الإبلاغ عن الآثار الجانبية التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا عانيت مما يلي:</strong></p><p dir="RTL">أعراض رد فعل تحسسي خطير، بما في ذلك تورم الوجه، وضيق في التنفس، وأعراض تشبه حمى القش، والطفح الجلدي، والقشعريرة، والصفير، والاحمرار، والتقيؤ، وارتفاع أو انخفاض ضغط الدم. في الحالات الشديدة؛ الحساسية المفرطة (رد فعل تحسسي مفاجئ وشديد مع صعوبة في التنفس، وتورم، يمكن أيضًا أن يحدث الدوار وتسارع ضربات القلب والتعرق وفقدان الوعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض جلطات الدم، بما في ذلك في الأوعية الدموية في الرئة والتي يمكن أن تظهر على شكل ضيق مفاجئ في التنفس أو ألم في الصدر أو سعال دموي أو إظهار الأوعية الدموية في الدماغ لأعراض مثل الضعف / التنميل، التشنجات، اضطرابات في التحدث، أو الصداع الشديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض التهاب البنكرياس، بما في ذلك آلام البطن، والغثيان، والقيء، وآلام الظهر، أو فقدان الشهية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">تحدّث إلى طبيبك في حال أصابك أي مما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة جداً </strong>(يمكن أن تؤثر على أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد الفعل التحسسي، بما في ذلك الطفح الجلدي، والحكة، والشرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابات بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفائح الدموية (نقص الصفيحات الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدم البيضاء (انخفاض عدد خلايا الدم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات العدلات، وهي نوع من خلايا الدم البيضاء التي تقاوم العدوى (قلة العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدم البيضاء (العدلات) مع الحمى بسبب العدوى (قلة العدلات الحموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الخلايا الليمفاوية، وهي نوع من خلايا الدم البيضاء التي تقاوم العدوى (انخفاض عدد الخلايا الليمفاوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في معدتك (ألم في البطن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السكر في الدم (فرط سكر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن (تدني الوزن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لفحص وظائف الكبد (زيادة الترانساميناسات، زيادة البيليروبين في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الألبومين (بروتين الدم) (نقص ألبومين الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور الكدمات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة (</strong>يمكن أن تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم الدم (الإنتان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي مفاجئ وشديد مع صعوبة في التنفس، وتورم، ودوار، وسرعة ضربات القلب، والتعرق، وفقدان الوعي (رد فعل تحسسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يوصف ببقع مسطحة متغيرة اللون ونتوءات مرتفعة ومحمرة (حطاطات) (طفح بقعي حطاطي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع احمرار والتهاب (طفح حمامي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي في موضع التسريب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات غير طبيعية لعامل تخثر الدم (امتداد زمن الثرومبوبلاستين الجزئي، انخفاض مضاد الثرومبين الثالث، انخفاض الفيبرينوجين في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف الكلى غير طبيعية (زيادة الكرياتينين في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات السكر في الدم (نقص السكر في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات الدم، بما في ذلك في الأوعية الدموية في الرئة والدماغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة (</strong>يمكن أن تؤثر على ما يصل إلى 1 من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية في أحد أوردة الدماغ الرئيسية (تجلط الدم في الجيب السهمي العلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية في الوريد العنقي (تجلط الدم في الوريد الوداجي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية في أوردة الأطراف (تجلط الدم في الأوردة العميقة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية </strong></p><p dir="RTL">إذا أصابتك أية آثار جانبية، فتحدث مع طبيبك أو الصيدلاني، وهذا يشمل أية آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عبر</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز اتصال الهيئة العامة للغذاء والدواء السعودية: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: <strong>npc.drug@sfda.gov.sa</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: <strong>https://ade.sfda.gov.sa</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الكويت</strong><strong>:</strong></p><p dir="RTL">&bull; الرقابة الدوائیة والغذائیة، وزارة الصحة، الكویت</p><p dir="RTL">- رقم الھاتف: 24811532+965-</p><p dir="RTL">- رقم الفاكس: 24811507+965-</p><p dir="RTL">- البرید الإلكتروني: Adr_reporting@moh.gov.kw</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول أيدي الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية والقارورة بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزين القوارير غير المفتوحة في الثلاجة (2 &ndash; 8 درجة مئوية) في وضعية مستقيمة. لا تقم بتجميدها. احتفظ بالقارورة في العبوة الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد إعداد جرعة في المحقنة، يمكن تخزين إنريلاز لمدة تصل إلى 8 ساعات في درجة حرارة الغرفة (15 - 25 درجة مئوية) أو لمدة 24 ساعة في الثلاجة (2 - 8 درجة مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد الإذابة في كيس المحلول الوريدي، يمكن تخزين إنريلاز لمدة تصل إلى 12 ساعة في درجة حرارة الغرفة (15 - 25 درجة مئوية) أو 24 ساعة في الثلاجة (2 - 8 درجة مئوية). يبدأ وقت التخزين بمجرد سحب المحلول من القوارير غير المفتوحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت وجود أي جزيئات في المحلول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستخدمها، حيث أن هذه التدابير سوف تساعد في حماية البيئة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي كريسانتاسباس<em> </em>مؤتلف. تحتوي كل قارورة على 10 ملغ من كریسانتاسباس المؤتلف في محلول 0.5 مل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي ثنائي هيدرات تريهالوز، كلوريد الصوديوم (انظر القسم 2 &quot;يحتوي إنريلاز<em> </em>على الصوديوم&quot;)، هيدروكسيد الصوديوم (لضبط الرقم الهيدروجيني)، فوسفات ثنائي الصوديوم، أحادي هيدرات فوسفات ثنائي هيدروجين الصوديوم، بوليسوربات 80 وماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">إنريلاز هو محلول شفاف مائل إلى اللون الأصفر قليلاً مخصص للتسريب أو الحقن ، خالي من الجسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي الكرتونة الواحدة على 3 قوارير زجاجية، تحتوي كل منها على 0.5 مل من محلول للتسريب أو الحقن .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حامل رخصة التسويق و</strong><strong>المصنع المسؤول عن تحرير الصنف</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">جاز للصناعات الدوائية ايرلندا المحدودة</p><p dir="RTL">الطابق الخامس</p><p dir="RTL">مركز تبادل ووترلو</p><p dir="RTL">طريق ووترلو</p><p dir="RTL">دبلن 4</p><p dir="RTL">D04 E5W7</p><p dir="RTL">ايرلندا</p><p dir="RTL">هاتف: +353 1 968 1631</p><p dir="RTL">البريد الإلكتروني: medinfo-int@jazzpharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>مصنع الشكل الصيدلاني:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">باثيون</p><p dir="RTL">تصنيع</p><p dir="RTL">الخدمات، ذ.م.م</p><p dir="RTL">5900 مارتن لوثر</p><p dir="RTL">كينغ جونيور.</p><p dir="RTL">الطريق السريع،</p><p dir="RTL">جرينفيل، كارولاينا الشمالية</p><p dir="RTL">27834-8628</p><p dir="RTL">الولايات المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أية معلومات بشأن هذا الدواء، يرجى الاتصال بالممثل المحلي لحامل رخصة التسويق في المملكة العربية السعودية و في الكويت:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المملكة العربية السعودية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">شركة بيولوجيكس المنطقة الحرة</p><p dir="RTL">شارع هبة الله الغفاري &ndash; السليمانية &ndash; المملكة العربية السعودية</p><p dir="RTL">ص.ب. 991 الرياض 11421</p><p dir="RTL">هاتف: +966 11 464 6955</p><p dir="RTL">فاكس: +966 11 463 4362</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ف <u>الكويت</u></p><p dir="RTL">&nbsp;Medinfo@biologixpharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Enrylaze® 10 mg/0.5 mL solution for infusion or injection. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
One vial contains 0.5 mL solution of 10 mg of recombinant crisantaspase*

The amino acid sequence is identical to native L asparaginase from Erwinia chrysanthemi (also known as crisantaspase).

An in-vitro activity assay demonstrated that 1 mg of recombinant crisantaspase approximates 1 000 U of native crisantaspase, consistent with the in-vivo comparisons from clinical trials. Serum asparaginase activity (SAA) exposures (Cmax, concentration at 48h & 72h and AUC) have been shown to be comparable for 25 mg/m2 recombinant crisantaspase and 25 000 U/m2 native crisantaspase, when administered intravenously or intramuscularly in healthy subjects.

*recombinant Erwinia chrysanthemi L asparaginase produced in Pseudomonas fluorescens by recombinant DNA technology.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Solution for infusion or injection.

Clear to opalescent, colourless to slightly yellow solution with a pH of 7.0 ± 0.5 and an osmolality: 290–350 mOsmol/Kg.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Enrylaze&reg; is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to <em>E. coli</em>-derived asparaginase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Enrylaze&reg; should be prescribed and administered by physicians and healthcare personnel experienced in the use of antineoplastic products. Appropriate resuscitation equipment and other agents necessary to treat anaphylaxis should be available when administering Enrylaze&reg;.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose of Enrylaze&reg; is:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Every 48&nbsp;hours</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&nbsp;mg/m<sup>2</sup> intramuscularly or intravenously</p><p>Or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monday/Wednesday/Friday</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&nbsp;mg/m<sup>2</sup> intramuscularly on Monday and Wednesday, and 50&nbsp;mg/m<sup>2</sup> intramuscularly on Friday; or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&nbsp;mg/m<sup>2</sup> intravenously on Monday and Wednesday, and 50&nbsp;mg/m<sup>2</sup> intramuscularly on Friday; or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&nbsp;mg/m<sup>2</sup> intravenously on Monday and Wednesday, and 50&nbsp;mg/m<sup>2</sup> intravenously on Friday</p><p><em>Recommended premedication</em></p><p>A consideration to premedicate patients with paracetamol, an H1 receptor blocker, and an H2 receptor blocker 30&ndash;60&nbsp;minutes prior to administration should be made when Enrylaze&reg; is being given intravenously to decrease the risk and severity of infusion related reaction/hypersensitivity reaction.</p><p><em>&nbsp;</em></p><p><em>Recommended monitoring</em></p><p>Asparaginase activity can vary between individuals, therefore trough SAA should be monitored. When administered every 48&nbsp;hours a trough asparaginase activity measurement should be performed at 48&nbsp;hours post dose. When dosing on a Monday/Wednesday/Friday schedule, trough SAA should be measured 72&nbsp;hours after the Friday dose and prior to administration of the following Monday dose. The dosing schedule or route of administration should then be individually adapted (see section 4.4).</p><p>&nbsp;</p><p>Therapy can be further adjusted according to local treatment protocols.</p><p>&nbsp;</p><p>The dose of Enrylaze&reg; is administered in mg/m<sup>2 </sup>and is not administered in units/m<sup>2</sup>, as used for other asparaginase preparations. Enrylaze&reg; is not interchangeable with other crisantaspase products to complete a cycle of treatment.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Hepatic impairment</em></p><p>Dose adjustment is not required for patients that develop total bilirubin &le;&nbsp;3&nbsp;times the Upper Limit of Normal (ULN) during treatment.</p><p>&nbsp;</p><p>Enrylaze&reg; should be withheld if total bilirubin is &gt;&nbsp;3&nbsp;times to &le;&nbsp;10&nbsp;times the ULN during treatment, treatment can continue once resolved. In the event of a severe occurrence (total bilirubin &gt;&nbsp;10&nbsp;times the ULN), treatment should be stopped and patients not rechallenged (see section 4.4).</p><p>&nbsp;</p><p>Dose adjustment is not required for patients with pre-existing mild or moderate hepatic impairment (total bilirubin &gt; 1 to 3 times the ULN or AST greater than the ULN). There are insufficient data in patients with pre-existing severe hepatic impairment to support a dose recommendation.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>There are insufficient data in patients with mild, moderate or severe renal impairment to support a dose recommendation.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>No dose adjustment is required in paediatric patients.</p><p>&nbsp;</p><p>The safety and efficacy of children aged younger than 1 month has not yet been established.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required in elderly patients.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Enrylaze&reg; is for intramuscular and/or intravenous use.</p><p>&nbsp;</p><p>For intramuscular use, limit the volume of Enrylaze&reg; at a single injection site to 2&nbsp;mL for patients with a body surface area (BSA) &gt;&nbsp;0.5&nbsp;m<sup>2</sup>, for patients with a BSA &lt;&nbsp;0.5&nbsp;m<sup>2</sup> limit the volume to 1&nbsp;mL. If the volume to be administered is greater than the mentioned limits, use multiple injection sites.</p><p>&nbsp;</p><p>For intravenous infusion, it is recommended to administer the dose over 2&nbsp;hours.</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before intravenous administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
•	History of severe hypersensitivity reactions to the active substance 
•	Hypersensitivity to any of the excipients listed in section 6.1
•	Severe pancreatitis 
•	History of severe pancreatitis during previous asparaginase therapy
•	Severe thrombosis during previous asparaginase therapy
•	Severe haemorrhagic events during previous asparaginase therapy

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><em>&nbsp;</em></p><p><u>Clinical monitoring</u></p><p><em>Asparaginase activity</em></p><p>SAA varies substantially between patients, when treatment is administered intravenously. The optimal SAA level is &ge;&nbsp;0.1&nbsp;U/mL; if this is not observed the dosing schedule should be individually adapted. When administering Enrylaze&reg; intravenously on a Monday/Wednesday/Friday schedule, trough SAA levels should be measured 72&nbsp;hours after the Friday dose and prior to the following Monday administration. If SAA levels &ge;&nbsp;0.1&nbsp;U/mL are not observed, administration of intramuscular Enrylaze&reg; or switching to a 48‑hour dosing interval (intravenous or intramuscular) should be considered. If SAA levels are monitored at 48‑hour intervals of intravenous Enrylaze&reg; administration and SAA levels &ge;&nbsp;0.1&nbsp;U/mL are not observed, administration intramuscularly should be considered (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity reactions</u></p><p>Grade 3 and 4 hypersensitivity reactions after the use of Enrylaze&reg; have occurred in patients during clinical trials (see sections 4.3 and 4.8). Hypersensitivity reactions may occur more frequently when treatment is administered intravenously in comparison to when treatment is administered intramuscularly.</p><p>&nbsp;</p><p>Because of the risk of serious allergic reactions, Enrylaze&reg; should be administered in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Enrylaze&reg; should be discontinued in patients with severe hypersensitivity reactions (see section 4.3).</p><p>&nbsp;</p><p><u>Pancreatitis</u></p><p>Pancreatitis has been reported in patients treated with Enrylaze&reg; in clinical trials (see section 4.8).</p><p>Patients with symptoms compatible with pancreatitis should be evaluated to establish a diagnosis.</p><p>&nbsp;</p><p>Enrylaze&reg; should be discontinued in patients that develop necrotising or haemorrhagic pancreatitis.</p><p>&nbsp;</p><p>In the case of elevations in lipase or amylase &gt;&nbsp;2&nbsp;times the ULN or symptomatic pancreatitis, Enrylaze&reg; should be withheld until the ULN and symptoms subside. After resolution of pancreatitis, treatment with Enrylaze&reg; may be resumed.</p><p>&nbsp;</p><p><u>Glucose intolerance</u></p><p>Cases of glucose intolerance have been reported in patients receiving Enrylaze&reg; in clinical trials (see section 4.8). Glucose levels in patients should be monitored at baseline and periodically during treatment. Insulin therapy should be administered as necessary in patients with hyperglycaemia.</p><p>&nbsp;</p><p><u>Coagulation disorders</u></p><p>Thrombotic and bleeding events, including sagittal sinus thrombosis and pulmonary embolism have been reported with L‑asparaginase therapy. Enrylaze&reg; treatment should be held for a thrombotic or haemorrhagic event until symptoms resolve; after resolution, treatment with Enrylaze&reg; may be resumed.</p><p>&nbsp;</p><p><u>Hepatotoxicity</u></p><p>Therapy that includes Enrylaze&reg; can cause hepatotoxicity as experienced during clinical trials (see section 4.8).</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of hepatotoxicity.&nbsp; Bilirubin and transaminases should be monitored prior to treatment and as clinically required during treatment with Enrylaze&reg;. In the event of severe liver toxicity, treatment with Enrylaze&reg; must be discontinued and supportive care provided.</p><p>&nbsp;</p><p><u>Neurotoxicity</u></p><p>Central nervous system (CNS) toxicity, including encephalopathy, seizures and CNS depression as well as posterior reversible encephalopathy syndrome (PRES) may occur during treatment with any asparaginase therapy.</p><p>&nbsp;</p><p>PRES may occur rarely during treatment with any asparaginase. This syndrome is characterised in magnetic resonance imaging (MRI) by reversible (from a few days to months) lesions/oedema, primarily in the posterior region of the brain. Symptoms of PRES essentially include elevated blood pressure, seizures, headaches, changes in mental state and acute visual impairment (primarily cortical blindness or homonymous hemianopsia).</p><p>&nbsp;</p><p>It is unclear whether the PRES is caused by asparaginase, concomitant treatment or the underlying diseases. PRES is treated symptomatically, including measures to treat any seizures. Discontinuation or dose reduction of concomitantly administered immunosuppressive medicinal products may be necessary. Expert advice should be sought.</p><p><u>&nbsp;</u></p><p><u>Contraception</u></p><p>Contraception should be used during treatment and for 3&nbsp;months after receiving the final dose of Enrylaze&reg;. Women should also undergo pregnancy testing before therapy with Enrylaze&reg; is initiated. Since an indirect interaction between oral contraceptives and Enrylaze&reg; cannot be ruled out, patients of childbearing potential should use effective non-hormonal contraceptive methods while undergoing treatment (see section 4.6).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say, essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No interaction studies have been performed.</p><p>&nbsp;</p><p><u>General</u></p><p>The possibility of interactions with medicinal products whose pharmacokinetics or pharmacodynamics are affected by asparaginase-induced changes in the liver function or plasma protein levels should be taken into account when administering asparaginase. Asparaginase may increase toxicity of other medicinal products through its effect on liver function.</p><p>&nbsp;</p><p><u>Vincristine</u></p><p>Administration of asparaginase concurrently or immediately before vincristine may be associated with increased toxicity of vincristine. Asparaginase inhibits hepatic clearance of vincristine.</p><p><u>&nbsp;</u></p><p><u>Methotrexate, cytarabine</u></p><p>Non-clinical data indicates that prior or concurrent administration of L‑asparaginase attenuates the effect of methotrexate and cytarabine. Administration of L‑asparaginase after methotrexate or cytarabine results in a synergistic effect. However, the clinical effect of sequence-dependent L‑asparaginase administration on the efficacy of methotrexate and cytarabine is unknown.</p><p>&nbsp;</p><p><u>Glucocorticoids</u></p><p>Administration of asparaginase with or immediately before glucocorticoids (e.g. prednisone) may change coagulation parameters, such as a decrease in fibrinogen and antithrombin III levels.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Women of childbearing potential/Contraception in males and females</u></p><p>Men and women should use contraception during treatment with Enrylaze&reg; containing chemotherapy. Because the time period following treatment with asparaginase when it is safe to become pregnant or father a child is unknown, effective contraception should be used in men and women for at least 3&nbsp;months after discontinuation. Since an indirect interaction between oral contraceptives and Enrylaze&reg; cannot be ruled out, patients of childbearing potential should use effective non-hormonal contraceptive methods while undergoing treatment (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>There are no data on the use of recombinant crisantaspase in pregnant women. Based on studies with <em>Erwinia chrysanthemi</em> L‑asparaginase in pregnant animals, recombinant crisantaspase can cause embryonic and foetal harm when administered to a pregnant woman (see section 5.3).</p><p>&nbsp;</p><p>Women of childbearing potential should undergo pregnancy testing before initiation of Enrylaze&reg;. Enrylaze&reg; should not be used during pregnancy, unless the clinical condition of the woman requires treatment and justifies the potential risk to the foetus. If the medicinal product is used during pregnancy, or if the patient becomes pregnant while receiving Enrylaze&reg;, the woman should be informed of the potential hazard to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether recombinant crisantaspase is excreted in human milk. Because of the potential for serious adverse reactions in breast-feeding infants/children, mothers should be advised not to breast-feed during Enrylaze&reg; therapy and for a period of two weeks after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No human data on the effect of recombinant crisantaspase on fertility are available. In a fertility and early embryonic development study in rats with <em>Erwinia chrysanthemi</em> crisantaspase, there were no effect on female or male fertility (margins of human exposure &lt;&nbsp;1) (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Enrylaze&reg; has minor influence on the ability to drive and use machines. This influence is based on the adverse reactions that may occur during treatment (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>Serious adverse reactions occurred in 59% of patients who received Enrylaze&reg; in a clinical trial. The most frequent serious adverse reactions were febrile neutropenia (29%), pyrexia (10%), vomiting (8%), sepsis (7%), medicinal product hypersensitivity (6%), nausea (6%), and pancreatitis (5%).</p><p>&nbsp;</p><p>The most common adverse reactions were anaemia (52%), vomiting (49%), thrombocytopenia (42%), neutropenia (41%), nausea (38%), febrile neutropenia (32%), fatigue (32%), pyrexia (32%), decreased appetite (29%), transaminase increased (29%), abdominal pain (27%), white blood cell count decreased (27%), headache (25%), diarrhoea (22%), and lymphocyte count decreased (20%).</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions reported in clinical trial are listed in Table 1 by system organ class and by frequency. The frequencies identified are from patients (n=228) who received 6 doses of Enrylaze&reg;, along with a multi-agent chemotherapeutic regimen. Certain adverse reactions listed below, such as reactions resulting from bone marrow suppression, and infections, are known to be associated with multi-agent chemotherapeutic regimens, and the contributory role of Enrylaze&reg; is not clear. In individual cases of adverse reactions, other medicinal products of the regimen may have contributed.</p><p>&nbsp;</p><p>Frequencies are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: Adverse reactions in patients receiving Enrylaze&reg; with multi-agent chemotherapy (Study JZP458-201)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sepsis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia, Thrombocytopenia, Neutropenia, Febrile neutropenia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Drug hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, Hypersensitivity</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite, Hyperglycaemia, Hypoalbuminemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypertriglyceridemia, Hypoglycaemia, Hyperammonaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Irritability</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Superior sagittal sinus thrombosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Jugular vein thrombosis, Deep vein thrombosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Vomiting, Nausea, Abdominal pain, Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash maculo-papular, Pruritus, Rash, Urticaria, Rash erythematous,</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pain in extremity</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue, Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site pain, Injection site reaction</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Transaminases increased, White blood cell count decreased, Lymphocyte count decreased, Weight decreased, Blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood creatinine increased , Activated partial thromboplastin time prolonged, Blood fibrinogen decreased, Antithrombin III decreased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications </strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Contusion</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infusion-related reaction</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Hypersensitivity</em></p><p>Hypersensitivity reactions were reported adverse reactions in the Enrylaze&reg; clinical trial. The incidence of medicinal product hypersensitivity was 11% and it was severe in 8% of patients. The incidence of anaphylactic reaction was 2%, and it was severe in all patients. Overall hypersensitivity reactions observed more frequently in patients who received Enrylaze&reg; intravenously. The frequency of hypersensitivity reactions leading to discontinuation was 10% (see section 4.4).</p><p>&nbsp;</p><p><em>Pancreatitis</em></p><p>Cases of pancreatitis including life threatening cases have been reported in the Enrylaze&reg; clinical trial. The incidence of pancreatitis was 7%; the incidence of serious events of pancreatitis was 5%; the incidence of life-threatening pancreatitis was 1%. One patient developed pancreatic pseudocyst after acute pancreatitis, which resolved without sequelae. The frequency of pancreatitis in Study JZP458‑201 which led to discontinuation was 5% (see section 4.4).</p><p>&nbsp;</p><p><u>Adults and other special populations</u></p><p>Although the safety profile of adults above 25&nbsp;years of age has not been studied, some adverse reactions, such as hepatotoxicity, thrombosis, and pancreatitis, have been reported more frequently in adults with acute lymphoblastic leukemia receiving other asparaginases than in paediatric patients.</p><p>&nbsp;</p><p><u>Immunogencity</u></p><p>It has been reported that there is no to little cross reactivity between crisantaspase and other <em>E. coli</em> derived asparaginase.</p><p>&nbsp;</p><p>As with all therapeutic proteins, there is a potential for immunogenicity. Immunogenicity assays are highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as assay methodology, sample handling, timing of sample collection, concomitant treatment, and underlying disease. For these reasons, comparison of the incidence of antibodies to Enrylaze&reg; with the incidence of antibodies to other products may be misleading.</p><p>&nbsp;</p><p>Analysis of patients receiving Enrylaze&reg; by either intramuscular injection (n=167) or intravenous infusion (n=61) showed that 116 of 228 (51%) patients had confirmed positive anti-drug antibodies (ADA) toward Enrylaze&reg;, 8 (7%) of these were ADA positive at pre dose&nbsp;1.</p><p>&nbsp;</p><p>A total of 23 (20%) patients who had ADAs experienced hypersensitivity reactions of which 6 (5%) had neutralising antibodies. Of the negative ADA patients 7/112 (6%) experienced a hypersensitivity reaction.</p><p>&nbsp;</p><p>During the course of treatment 73 (63%) patients became ADA negative at least once.</p><p>&nbsp;</p><p><em>Intravenous infusion</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A total of 34 (56%) patients were found to be ADA positive.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 patient was ADA positive at pre dose&nbsp;1.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33 patients developed ADA toward Enrylaze&reg; following administration of Enrylaze&reg;. 18 of these patients subsequently became ADA negative at least once during the study.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12 (35%) experienced hypersensitivity reactions during the study, and of these patients 2 had neutralising antibodies. Of the negative ADA patients 4/27 (15%) experienced a hypersensitivity reaction.</p><p><em>&nbsp;</em></p><p><em>Intramuscular injection</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A total of 82 (49%) patients were found to be ADA positive.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7 patients were ADA positive at pre dose&nbsp;1.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 75 patients developed ADA toward Enrylaze&reg; following administration of Enrylaze&reg;. 55 of these patients subsequently became ADA negative at least once during the study.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11 (13%) patients experienced hypersensitivity reactions, and of these patients 4 had neutralising antibodies. Of the negative ADA positive patients 7/85 (8%) experienced a hypersensitivity reaction.</p><p>&nbsp;</p><p>The presence of ADA does not appear to correlate with the occurrence of hypersensitivity reactions. SAA levels were not impacted for applicable ADA positive patients as they maintained SAA levels &ge;&nbsp;0.1 U/mL at all available 48- and 72‑hour time points during Course 1. No impact on the pharmacokinetics of Enrylaze&reg; was observed and ADA status was not found to be a significant factor in population pharmacokinetic analysis.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The majority of the patients in Study JZP458‑201 were children &lt;&nbsp;18&nbsp;years&nbsp;old 197/228 (86%) and therefore a comparison of frequency and severity in adverse reactions versus other age groups is not suitable.</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any side effect(s)</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&bull; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No case of Enrylaze&reg; overdose with clinical symptoms has been reported and there is no specific antidote. Treatment is symptomatic and supportive.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Other antineoplastic agents ATC code: L01XX02.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Asparaginase is an enzyme that catalyses the conversion of the amino acid L‑asparagine into L‑aspartic acid and ammonia. The pharmacological effect of Enrylaze&reg; is based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize asparagine, and therefore is dependent on an exogenous source of asparagine for survival.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The efficacy and safety of Enrylaze&reg; was determined in the clinical trials, an open-label, two-part, multi-cohort, multi-centre, multi-agent chemotherapeutic trial that treated 228&nbsp;adult and paediatric patients with ALL or LBL who developed hypersensitivity to a long-acting <em>E. coli</em>-derived asparaginases. The median age of patients was 10&nbsp;years (range, 1&nbsp;to&nbsp;25&nbsp;years).</p><p>&nbsp;</p><p>Prior long-acting <em>E. coli</em>-derived asparaginase treatments included pegaspargase for all patients apart from one who received other type of <em>E. coli</em>-derived asparaginase. In Study JZP458‑201, 190 (83%) patients experienced a hypersensitivity (Grade &ge;&nbsp;3) to a long-acting <em>E. coli</em>-derived asparaginases, 15&nbsp;(7%) patients experienced silent inactivation, and 23&nbsp;(10%) patients experienced an allergic reaction with inactivation. The number of courses of Enrylaze&reg; received ranged from 1 to 15.</p><p>&nbsp;</p><p>Patients received 6 doses of Enrylaze&reg;, either intramuscularly at 25&nbsp;mg/m<sup>2</sup> or 37.5&nbsp;mg/m<sup>2</sup> three times a week (Monday/Wednesday/Friday), or 25&nbsp;mg/m<sup>2</sup> on Monday and Wednesday then 50&nbsp;mg/m<sup>2</sup> on Friday by intravenous infusion or an intramuscular injection as a replacement for each dose of <em>E. coli</em> derived asparaginase remaining on a patient&rsquo;s treatment plan.</p><p>&nbsp;</p><p>The determination of efficacy was based on demonstration of the achievement and maintenance of nadir serum asparaginase activity (NSAA) levels &ge;&nbsp;0.1&nbsp;U/mL. Serum trough asparaginase activity &ge;&nbsp;0.1&nbsp;U/mL has been demonstrated to correlate with asparagine depletion that predicts clinical efficacy (see section 5.2).</p><p>&nbsp;</p><p>Observed NSAA levels during the clinical trials for indicated dosing schedules are presented in Table&nbsp;2.</p><p>&nbsp;</p><p><strong>Table 2: Observed NSAA levels </strong><strong>&ge;&nbsp;0.1</strong>&nbsp;<strong>U/mL </strong><strong>during the clinical trials</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:92%"><thead><tr><td style="vertical-align:top"><p>Time Point</p></td><td style="vertical-align:top"><p>Intramuscularly&nbsp;25&nbsp;(MW)/<br />50&nbsp;(F)&nbsp;mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>Intravenously&nbsp;25&nbsp;(MW)/<br />50&nbsp;(F)&nbsp;mg/m<sup>2</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Last 48‑hour</p></td><td style="vertical-align:top"><p>95.9%</p><p>[90.4%, 100.0%]</p></td><td style="vertical-align:top"><p>&nbsp;89.8%</p><p>[82.1%, 97.5%]</p></td></tr><tr><td style="vertical-align:top"><p>Last 72‑hour</p></td><td style="vertical-align:top"><p>89.8%</p><p>[81.3%, 98.3%]</p></td><td style="vertical-align:top"><p>40.0%</p><p>[26.4%, 53.6%]</p></td></tr></tbody></table><p>MW=Monday, Wednesday</p><p>MWF=Monday, Wednesday, Friday</p><p>&nbsp;</p><p>The other recommended dosing schedules are based on interpolation from pharmacokinetic (PK) and response rates observed with the very similar investigated regimens.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>No clinically significant difference is expected in probability of achieving a therapeutic NSAA &ge;&nbsp;0.1&nbsp;U/mL based on age (1&nbsp;month to 39&nbsp;years) following the proposed Body surface area (BSA)‑based dosing regimens.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>The PK of Enrylaze&reg; was determined based on SAA. Patients received 6&nbsp;doses of Enrylaze&reg; at various doses intramuscularly on Monday, Wednesday and Friday or 25&nbsp;mg/m<sup>2</sup> administered intramuscularly or intravenously on Monday and Wednesday and 50&nbsp;mg/m<sup>2</sup> on Friday as a replacement for each dose of a long-acting <em>E. coli</em>-derived asparaginase remaining on their original treatment plan. Recombinant crisantaspase maximum SAA (C<sub>max</sub>) and area under the SAA-time curve (AUC) increase approximately proportionally over a dose range from 12.5 to 50&nbsp;mg/m<sup>2</sup>. The trough SAA at 48‑hour (C<sub>trough,48</sub>) or 72‑hour (C<sub>trough,72</sub>) post the last dose for recombinant crisantaspase are summarised in Table 3.</p><p>&nbsp;</p><p><strong>Table 3: Enrylaze&reg; pharmacokinetic parameters based on SAA </strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:549px"><tbody><tr><td rowspan="3"><p><strong>PK</strong></p><p><strong>Parameter<sup>a</sup></strong></p></td><td colspan="4"><p><strong>Mean (95% CI) after last dose</strong></p></td></tr><tr><td colspan="2"><p><strong>25/25/50&nbsp;mg/m<sup>2</sup></strong></p><p><strong>Monday, Wednesday, Friday</strong></p></td><td colspan="2"><p><strong>25/25/50&nbsp;mg/m<sup>2</sup></strong></p><p><strong>Monday, Wednesday, Friday</strong></p></td></tr><tr><td colspan="2"><p><strong>Intramuscularly</strong></p></td><td colspan="2"><p><strong>Intravenously</strong></p></td></tr><tr><td><p>C<sub>trough,48</sub> (U/mL)</p></td><td><p>N =49</p></td><td><p>0.66</p><p>(0.54‑0.77)</p></td><td><p>N = 59</p></td><td><p>0.25</p><p>(0.20‑0.29)</p></td></tr><tr><td><p>C<sub>trough,72&nbsp;</sub>(U/mL)</p></td><td><p>N=49</p></td><td><p>0.47</p><p>(0.35‑0.59)</p></td><td><p>N =50</p></td><td><p>0.10</p><p>(0.07‑0.13)</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a</sup>: C<sub>trough,48</sub>: Trough SAA at 48 hour post the last 25 mg/m<sup>2</sup> dose in cycle 1; C<sub>trough,72</sub>: Trough SAA at 72 hour post the last 50 mg/m<sup>2</sup> dose in cycle 1.</p><p>&nbsp;</p><p><u>Absorption </u></p><p>The median T<sub>max</sub> of recombinant crisantaspase is 16&nbsp;hours following intramuscular administration. The mean absolute bioavailability for intramuscular administration is 38%.</p><p>&nbsp;</p><p><u>Distribution </u></p><p>Following intravenous administration, the geometric mean (%CV) volume of distribution of recombinant crisantaspase is 1.75&nbsp;L/m<sup>2</sup> (14%).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Recombinant crisantaspase is expected to be metabolized into small peptides by catabolic pathways.</p><p><em>&nbsp;</em></p><p><u>Elimination </u></p><p>Following intravenous administration, the geometric mean (%CV) clearance of recombinant crisantaspase is 0.14&nbsp;L/hour/m<sup>2</sup> (20%).</p><p>&nbsp;</p><p>The geometric mean (%CV) half-life is 8.6&nbsp;hours (13%) following intravenous administration and 18.8&nbsp;hours (11%) following intramuscular administration.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Renal and hepatic impairment</em></p><p>There was no dedicated study on renal or hepatic impairment with Enrylaze&reg;.</p><p>&nbsp;</p><p>During treatment dose adjustment is not required for patients with total bilirubin &le;&nbsp;3&nbsp;times the Upper Limit of Normal; there is limited data with Enrylaze&reg; in patients with total bilirubin &gt;&nbsp;3&nbsp;times to &le;&nbsp;10&nbsp;times the ULN.</p><p>&nbsp;</p><p>Dose adjustment is not required for patients with pre-existing mild or moderate hepatic impairment (total bilirubin &gt;&nbsp;1 to 3&nbsp;times the ULN or AST &gt;&nbsp;than the ULN). There are insufficient data in patients with pre-existing severe hepatic impairment to support a dose recommendation.There are insufficient data in patients with mild, moderate or severe renal impairment to support a dose recommendation.</p><p>&nbsp;</p><p><em>Age, weight, body surface area and sex </em></p><p>There were no clinically significant differences in the pharmacokinetics of Enrylaze&reg; based on weight (9 to 131&nbsp;kg) or sex (n=138 male; n=88 female) after the dose was adjusted by body surface area (BSA).</p><p>&nbsp;</p><p>The volume of distribution and clearance of recombinant crisantaspase increase with increasing BSA (0.44 to 2.53&nbsp;m<sup>2</sup>).</p><p>&nbsp;</p><p>Age impacts absorption rate constant whereas younger subjects have higher absorption rate constant value, leading to earlier T<sub>max</sub>.</p><p><strong>&nbsp;</strong></p><p><em>Race</em></p><p>Black or African American patients (n=24) had 25% lower clearance which may increase SAA exposure compared to population average (n=226). No dose adjustment is needed in African American population. There were no clinically significant differences in clearance between Hispanic (n=73) and Non-Hispanic (n=139) patients.</p><p>&nbsp;</p><p><em>Neutralising antibodies</em></p><p>As with other asparaginase preparations, development of specific neutralising antibodies were identified with repeated dosing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>In a study, recombinant crisantaspase was administered intravenously to groups of rats for up to 14&nbsp;consecutive days. Adverse effects in na&iuml;ve animals, which were typical for asparaginases, were noted at exposures greater than 3.6 times the maximum human exposure.</p><p>&nbsp;</p><p>Carcinogenicity, mutagenicity, and reproductive toxicity studies have not been conducted with Enrylaze&reg;.</p><p>&nbsp;</p><p>In embryofoetal development studies in rats and rabbits, <em>Erwinia chrysanthemi</em> L‑asparaginase produced maternal toxicity, increased resorptions, post implantation loss, embryofoetal toxicity, and/or gross abnormalities at exposures lower than those observed clinically (margins of exposure &lt;&nbsp;1).</p><p>&nbsp;</p><p>In rat fertility and pre- and post-natal development studies with <em>Erwinia chrysanthemi</em> L‑asparaginase, there were no adverse effects on fertility or development, but the exposures were lower than those observed clinically (margins of exposure &lt;&nbsp;1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Trehalose dihydrate</p><p>Sodium chloride</p><p>Sodium hydroxide (for pH adjustment)</p><p>Disodium phosphate</p><p>Sodium dihydrogen phosphate monohydrate</p><p>Polysorbate&nbsp;80</p><p>Water for injection</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. This includes infusion of other medicinal products using the same infusion line as Enrylaze&reg;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Unopened vial
3 years.

In-use stability data
From a microbiological point of view, unless the method of opening/dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Intramuscular preparation
Chemical and physical in-use stability for intramuscular preparations in a polypropylene syringe has been demonstrated for up to 8 hours at room temperature (15 °C–25 °C) or 24 hours when refrigerated (2 °C–8 °C).

Intravenous preparation 
Chemical and physical in-use stability for intravenous preparations has been demonstrated for up to 12 hours at room temperature (15 °C–25 °C) or 24 hours when refrigerated (2 °C–8 °C). The storage times start from withdrawing the required volume from the unopened vials. The storage time in the polyethylene inner lined intravenous bag includes the 2 hour administration time (see section 6.6).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C&ndash;8&nbsp;&deg;C) in an upright position.</p><p>&nbsp;</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>2&nbsp;mL Type 1 clear borosilicate glass vial sealed with a halobutyl rubber stopper and aluminium overseal and a violet plastic cap.</p><p>&nbsp;</p><p>Pack size: 3&nbsp;vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Precautions</u></p><p>Compatibility has been demonstrated in the following materials. No other materials have been studied.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syringes made of polypropylene</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous infusion sets made of PVC, polyolefin, polyamide, and ethylene vinyl acetate</p><p><u>&nbsp;</u></p><p><u>Preparation instructions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determine the posology, and number of vials of Enrylaze&reg; based on the individual patient&rsquo;s BSA as outlined in section 4.2. More than one vial may be needed for a full dose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the appropriate number of vials of Enrylaze&reg; from the refrigerator</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake the vials</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each vial should be inspected for particles. If particles are observed and/or the liquid in the vial is not clear, the vial must not be used</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the required volume of Enrylaze&reg; into a syringe</p><p><em>&nbsp;</em></p><p><em>Subsequent steps for intravenous infusion preparation</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The prepared dose of Enrylaze&reg; in the syringe should be further diluted in an infusion bag containing 100&nbsp;mL of sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous infusion prepared dose should be a clear liquid free from visual particulates.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If particles are observed in the intravenous infusion prepared dose, the solution must not be used</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The start of storage mentioned starts from withdrawing the required volume from the vial (see section 6.3)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 12- or 24‑hour storage time includes the recommended 2‑hour infusion time</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Jazz Pharmaceuticals Ireland Ltd
5th Floor
Waterloo Exchange
Waterloo Road
Dublin 4
D04 E5W7
Ireland 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>